Patents Examined by Christine J. Saoud
  • Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same
    Patent number: 11142557
    Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 12, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Jun Hwan Kim, Seyoung Lim, Minji Seo, Hyun Ho Choi, Dohoon Kim, Mi Kyeong Ju, Ju-Young Park, Byung Hyun Choi, Jun Kyung Lee, Jong Gyun Kim, Su Youn Nam
  • Methods of screening compounds useful for treatment of a liver disease
    Patent number: 11141423
    Abstract: Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: October 12, 2021
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Lakshmi A. Devi, Raphael Rozenfeld
  • Antibodies and antibody fragments for binding to NAV1.9 polypeptides and methods for using same to treat pain-related disease
    Patent number: 11136382
    Abstract: The present invention provides an antibody or antibody fragment thereof for a targeted cytomembrane voltage-gated sodium channel ? subunit Nav1.9. The specific binding target is a S3-4 ring of a voltage sensor paddle of a domain II of the voltage-gated sodium channel ? subunit. The antibody or antibody fragment thereof is able to inactivate a voltage sensor valve, to make sodium ions unable to enter nerve cells normally, thereby achieving the effect of treating and relieving pains.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: October 5, 2021
    Assignee: POPULAS BIOPHARMACEUTICAL (WUHAN) LIMITED
    Inventor: Daichang Yang
  • Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same
    Patent number: 11136364
    Abstract: The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 5, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Jun Hwan Kim, Seyoung Lim, Minji Seo, Hyun Ho Choi, Dohoon Kim, Mi Kyeong Ju, Ju-Young Park, Seul Gi Kim, Sangmyoun Lim, Jong Gyun Kim, Su Youn Nam
  • Aflibercept formulations and uses thereof
    Patent number: 11135266
    Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 5, 2021
    Assignee: Just-Evotec Biologics, Inc.
    Inventors: Bruce A. Kerwin, Julee A. Floyd, Alison J. Gillespie, Christine C. Siska
  • Nucleic acids encoding FGF21-Fc fusion proteins
    Patent number: 11129874
    Abstract: The invention relates to nucleic acids encoding fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are vectors and host cells comprising the same and methods of producing the fusion proteins.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 28, 2021
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis
    Patent number: 11103554
    Abstract: The invention relates to methods of using variants of fibroblast growth factor 19 (FGF19) for reducing bile acid synthesis in a subject having cirrhosis.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: August 31, 2021
    Assignee: NGM BIOPHARMACEUTICALS, INC.
    Inventors: Lei Ling, Jian Luo
  • Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
    Patent number: 11103558
    Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 31, 2021
    Assignee: Duke University
    Inventor: Ashutosh Chilkoti
  • High concentration VEGF receptor fusion protein containing formulations
    Patent number: 11103552
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 31, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
    Patent number: 11097005
    Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: August 24, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Sook Kyung Chang, Lydia Lynch
  • Treatment of Hodgkin lymphoma using an anti-PD-1 antibody
    Patent number: 11083790
    Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 10, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventor: Benedetto Farsaci
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11084865
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 10, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
    Patent number: 11072640
    Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 27, 2021
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11066458
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 20, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Compositions comprising fusion variants of FGF19 polypeptides
    Patent number: 11065302
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: July 20, 2021
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Compositions comprising variants and fusions of FGF19 polypeptides
    Patent number: 11066454
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: July 20, 2021
    Assignee: NGM BIOPHARMACEUTICALS, INC.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Method for treating eye diseases with a fusion protein of a tissue-penetrating peptide and anti-vascular endothelial growth factor
    Patent number: 11052130
    Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 6, 2021
    Assignee: ILDONG PHARM CO., LTD.
    Inventors: Seong Beom Kim, Hyei Yoon Jung, Seok Woo Yang, Hyuk Sang Kwon, Jae-Hoon Kang, Yong-Sung Kim
  • Formulation of growth hormone albumin-binder conjugate
    Patent number: 11045523
    Abstract: The present invention relates to compositions of growth hormone albumin-binder conjugates including pharmaceutical formulations. The compositions are able to provide initial and long term stability of the growth hormone albumin-binder conjugate, rendering such compositions suited for use as a pharmaceutical formulation.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 29, 2021
    Assignee: NOVO NORDISK HEALTHCARE AG
    Inventors: Jette Nielsen, Marie Eskling, Stina Granzau Christensen
  • Immunomodulatory antibodies and methods of use thereof
    Patent number: 11034770
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: June 15, 2021
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
  • Light chain variable regions
    Patent number: 11033634
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: June 15, 2021
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao